BioCryst Pharma (BCRX) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
BioCryst Reports Third Quarter 2017 Financial Results
November 7, 2017 6:00 AM ESTBCX7353 Phase 3 program agreed with FDA and EMA
U.S. Orphan Drug designation for BCX7353 received from FDA
RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) announced today financial results for the third quarter ended September 30, 2017.
Now that we have... More
